Mylocar 60 mg Injection: Advanced Proteasome Inhibitor Therapy
Extensive Product Profile: Understanding Mylocar 60 mg Injection
- Multiple Myeloma Management: Indicated for patients who have received at least one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- Tumor Lysis Prevention: Acts directly on malignant plasma cells in the bone marrow to control disease progression and alleviate bone pain.
- Proteasome Inhibition: Carfilzomib binds irreversibly to the N-terminal threonine-containing active sites of the 20S proteasome in the cell.
- Protein Accumulation: By suppressing the normal degradation of intracellular proteins, it causes an accumulation of misfolded proteins, triggering cell cycle arrest and apoptosis (programmed death) of malignant cells.
- Administration Route: Administered via intravenous (IV) infusion over 10 to 30 minutes, depending on the dosage regimen prescribed by an oncologist.
- Pre-medication: Often administered with Dexamethasone and adequate intravenous hydration to reduce the incidence and severity of infusion-related reactions and tumor lysis syndrome.
- Contraindications & Precautions: Not recommended for use during pregnancy.
Both male and female patients must use effective contraception during and for several months following treatment.
Safety, Side Effects, and MonitoringMylocar 60 mg Injection is a potent clinical formulation and requires medical supervision:
- Hematologic Monitoring: Routine assessment of complete blood count (CBC) is necessary due to the risk of thrombocytopenia and neutropenia.
- Common Side Effects: Fatigue, nausea, dyspnea, diarrhea, fever, and anemia.
- Toxicity Management: Patients must be monitored for signs of cardiac events (heart failure, ischemia), pulmonary toxicity, and hepatic or renal impairment. Dosage reduction or interruption may be clinically indicated.
Why Partner with Ernest Impex for Global Sourcing?Sourcing through Ernest Impex ensures you receive professional-grade, secured supply-chain services:
- Traceability: Every shipment is provided with a full Certificate of Analysis (COA) and complete batch traceability.
- Regulatory Support: We facilitate document clearance and supply chain logistics in compliance with TGA, HSA, and US-FDA/MHRA guidelines.
- Cold-Chain Integrity: Packed in strict compliance with cold-chain protocols (stored between
$2^\circ\text{C}$ and $8^\circ\text{C}$) to prevent degradation from temperature variations or light exposure. - Secure Bulk Supply: Consistent inventory availability for institutional healthcare tenders, pharmacies, and specialty clinics.
π Contact Ernest Impex β Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
π Websites:
π§ Email:
π¦ Business Type: Exporter | Bulk Supplier | Distributor
π² WhatsApp: +91 93599 02383
π